Dublin, July 19, 2024 (GLOBE NEWSWIRE) -- The "India Pharmaceutical Manufacturing Market Size, Share & Trends Analysis Report by Dosage Form (Tablets, Injectables), Manufacturing Type (In-house, Contract), Therapeutic Category (Endrocrinology, Cardiovascular), and Segment Forecasts, 2024-2030" report has been added to ResearchAndMarkets.com's offering.
The India pharmaceutical manufacturing market size is expected to reach USD 35.38 billion by 2030, growing at a CAGR of 10.5% with growth attributed to the rapid adoption of advanced technologies in clinical research, a rise in diversity & prevalence of diseases, and increased outsourcing activities due to intensified R&D efforts.
Moreover, several initiatives are taken up by public and government organizations to enhance R&D attempts and further boost market growth. For instance, in October 2021, the Department of Pharmaceuticals in India introduced a new policy to reduce the approval time for innovative products by at least 50% within the next 2 years, promoting R&D activities within the country. 
The increasing prevalence of cancer, cardiovascular disease, diabetes, and infectious diseases is expected to be a high-impact-rendering driver for the market over the next 6 years. The increasing shift of individuals towards unhealthy lifestyles such as smoking, increasing incidence of obesity, and more individuals experiencing dietary irregularities is the major cause of increased prevalence of cardiovascular diseases among the population. Moreover, the prevalence of diabetes across the country is increasing, thereby surging the patient pool for associated pharmaceuticals. Moreover, healthcare has grown to be one of the most important areas of the Indian economy, both in revenue and employment.
A continuous increase in clinical trials of pharmaceutical products is expected to create numerous opportunities for market growth in the coming years. In 2020, India's contribution to global clinical trial activity reached 8.3%, marking an increase compared to the previous decade's average of 6.2%. In oncology, India accounted for 9.0% of the share in 2020, a decrease from the 5-year and 10-year averages of 12.4% and 13.4% respectively. For respiratory-related trials, India held an 8.7% share in 2020, surpassing the 5-year and 10-year averages of 6.1% & 6.5%, respectively. In metabolic disorders, India's share was 8.5% in 2020, lower than the 5-year average of 13.2% and the 10-year average of 14.1%.
India is the world's third-largest producer of pharmaceuticals by volume and the twelfth-largest producer by value. With a 20% volume share of worldwide generic medication supply, the sector leads the globe in vaccine production and sales, accounting for 60% of the global market. From April 2000 to December 2022, total FDI in the pharmaceutical sector was estimated at USD 21.22 billion. In addition, the Indian pharmaceutical industry is worth over USD 50 billion, with exports accounting for over USD 25 billion. India accounts for over 20% of global generic medicine exports. Thus, increasing pharmaceutical R&D spending is expected to propel the market over the projected timeframe.
Key players operating in the market are developing innovative technologies and services to overcome the challenges in pharmaceutical manufacturing. For instance, in September 2023, Akums Drugs and Pharmaceuticals Limited announced the launch of Tamsulosin + Tadalafil capsule, a combination therapy approved by DCGI in the Indian market for the management of lower urinary tract symptoms and erectile dysfunction in men. The company announced its launch with an aim to expand its urology segment.
India Pharmaceutical Manufacturing Market Report Highlights
- Based on dosage form, tablet segment dominated the market and is anticipated to grow at fastest growth over the forecast period owing to the widespread availability of tablet-based products in various formulations, including film-coated, enteric-coated, orally disintegrating, and effervescent tablets.
- The contract manufacturing segment dominated the market attributed to benefits associated with outsourced services that help enhance the efficiency of manufacturing procedures.
- Based on therapeutic category, the cardiovascular segment is expected to grow at fastest rate owing to the rising prevalence of cardiovascular diseases and an increasing investment in R&D for the development of innovative drugs.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 120 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value (USD) in 2023 | $17.79 Billion |
| Forecasted Market Value (USD) by 2030 | $35.38 Billion |
| Compound Annual Growth Rate | 10.5% |
| Regions Covered | India |
Key Topics Covered:
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
2.1 Market Snapshot
2.2 Dosage Form and Manufacturing Type Snapshot
2.3 Therapeutic Category Segment Snapshot
2.4 Competitive Landscape Snapshot
Chapter 3 Indian Pharmaceutical Manufacturing Market Variables, Trends, and Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.1.1 Global Pharmaceutical Market
3.2 Market Dynamics
3.2.1 Market Driver Analysis
3.2.1.1 Rising Pharmaceutical R&D Spending
3.2.1.2 Advancements in Pharmaceutical Manufacturing Technologies
3.2.1.3 Rising Geriatric Population and Prevalence of Chronic Disorders
3.2.2 Market Restraint Analysis
3.2.2.1 Challenges in Pharma Supply Chain
3.2.2.2 Inadequate Training and Motivation for Research and Innovations Efforts
3.3 Market Analysis Tools
3.3.1 Industry Analysis: Porter's Five Forces
3.3.2 Macroeconomic Analysis
3.4 Current & Future Market Opportunity Analysis
3.4.1 Current Opportunity Analysis
3.4.1.1 Increase in Clinical Trials
3.4.1.2 Increasing Investment and Funding in Pharmaceutical it
3.4.2 The Future of Indian Manufacturing
3.5 Queries/Request Raised by CMOs
3.6 List of Key 5 Solid Dosage Drugs for Each Therapeutic Area
Chapter 4 India Pharmaceutical Manufacturing Market - Segment Analysis, by Dosage Form, 2018-2030 (USD Million)
4.1 India Pharmaceutical Manufacturing Market: Dosage Form Movement Analysis
4.2 India Pharmaceutical Manufacturing Market Estimates & Forecast, by Dosage Form (USD Million)
4.3 Penetration & Growth Prospect Mapping for Dosage Form, 2023
4.3.1 Tablets
4.3.1.1 Tablets Market, 2018-2030 (USD Million)
4.3.2 Capsules
4.3.2.1 Capsules Market, 2018-2030 (USD Million)
4.3.2.2 Soft Gelatin Capsule
4.3.2.3 Hard Gelatin Capsules
4.3.2.4 Others
4.3.3 Injectables
4.3.4 Others
Chapter 5 India Pharmaceutical Manufacturing Market - Segment Analysis, by Manufacturing Type, 2018-2030 (USD Million)
5.1 India Pharmaceutical Manufacturing Market: Manufacturing Type Movement Analysis
5.2 India Pharmaceutical Manufacturing Market Estimates & Forecast, by Manufacturing Type (USD Million)
5.3 Penetration & Growth Prospect Mapping for Manufacturing Type, 2023
5.3.1 In-House
5.3.2 Contract
5.3.2.1 Contract Manufacturing Market, 2018-2030 (USD Million)
Chapter 6 India Pharmaceutical Manufacturing Market - Segment Analysis, by Therapeutic Category, 2018-2030 (USD Million)
6.1 India Pharmaceutical Manufacturing Market: Therapeutic Category Movement Analysis
6.2 India Pharmaceutical Manufacturing Market Estimates & Forecast, by Therapeutic Category (USD Million)
6.3 Penetration & Growth Prospect Mapping for Therapeutic Category, 2023
6.4 Endocrinology
6.4.1 Canagliflozin
6.4.1.1 Approval
6.4.1.2 Patent Expiry
6.4.1.3 Available Combinations
6.4.1.4 Countries the Drug is Available in
6.4.1.5 Trends
6.4.2 Empagliflozin
6.4.3 Semaglutide
6.4.4 Tirzepatide
6.4.5 Linagliptin
6.4.6 Alogliptin
6.4.7 Trelagliptin
6.4.8 Myo-Inositol
6.5 Cardiovascular
6.5.1 Treprostinil
6.5.2 Azilsartan
6.5.3 Azilsartan+Amlodipine
6.5.4 Amlodipine + Lisinopril
6.5.5 Sparsentan
6.5.6 Esaxerenone
6.6 CNS
6.6.1 Cariprazine
6.6.2 Brexpiprazole
6.6.3 Lisdexamfetamine
6.6.4 Vortioxetine
6.6.5 Mirogabalin Besylate
6.6.6 Lasmiditan
6.6.7 Siponimod
6.7 Analgesics
6.7.1 Ibuprofen+Famotidine
6.8 Antacid
6.8.1 Pantoprazole Gastro Resistant
6.9 Antibiotic
6.9.1 Doxycycline
6.9.2 Tedizolid
6.10 Antifungal
6.10.1 Posaconazole
6.11 Antiprotozoal
6.11.1 Nitazoxanide
6.12 Hematology
6.12.1 Lenalidomide
6.12.2 Daprodustat
6.12.3 Roxadustat
6.12.4 Edoxaban
6.12.5 Avatrombopag
6.13 Others
6.13.1 Linaclotide
6.13.2 Apremilast
6.13.3 Tegoprazan
6.13.5 Vonoprazan
6.13.6 Rolapitant
6.13.7 Elagolix
Chapter 7 Global Oncology Pharmaceutical Manufacturing Market
7.1 List of Cancer Molecules Going Off Patent Between 2023 and 2030
7.2 Global Overview
7.3 Market Opportunities, by Type of Cancer
Chapter 8 India Injectables Pharmaceutical Manufacturing Market
8.1 Complete India Market Overview
8.2 Exports in Injectable Formulation
8.2.1 Therapeutic Category
8.2.1.1 Endocrinology
8.2.1.2 Cardiovascular
8.2.1.3 CNS
8.2.1.4 Analgesics
8.2.1.5 Antacid
8.2.1.6 Antibiotic
8.2.1.7 Antifungal
8.2.1.8 Antiprotozoal
8.2.1.9 Hematology
8.2.1.10 Others
8.2.2 Dosage Form
8.2.2.1 Intravenous
8.2.2.2 Subcutaneous
8.2.2.3 Intramuscular
8.2.2.4 Others
Chapter 9 Competitive Landscape
9.1 Participants' Overview
9.2 Financial Performance
9.3 Public Players Financial Overview
9.3.1 Alkem Laboratories Ltd.
9.3.1.1 Alkem's Performance in Key Therapeutic Segments
9.3.1.2 Performance of Alkem's Top 10 Brands
9.3.2 Sun Pharmaceutical Industries Ltd.
9.3.2.1 India Business Therapeutic Revenue Break-Up
9.3.2.2 Business-Wise Revenue Share
9.3.3 Ajanta Pharma Ltd.
9.3.3.1 Focused Presence in Key Therapy Areas
9.3.4 Cipla Inc.
9.3.4.1 Manufacturing Capabilities Highlights (in Million Units) FY 2022-23
9.3.4.2 Global Presence
9.3.4.3 Branded Prescription Business
9.3.4.4 API Manufacturing Capability
9.3.5 Eris Lifesciences
9.3.5.1 Eris Lifesciences Performance in Key Therapeutic Segments
9.3.6 Lupin
9.3.6.1 Lupin's Therapy-Wise Ranking
9.3.7 Glenmark Pharmaceuticals Ltd.
9.3.7.1 Revenue Distribution by Geographies
9.3.7.2 Top Brands of Glenmark in Top 300 of IPM
9.3.8 Torrent Pharmaceuticals Ltd.
9.3.8.1 Revenue Distribution by Geographies
9.4 Participant Categorization
9.4.1 Key Company Market Share Analysis
9.4.2 Strategy Mapping
9.4.2.1 Acquisition
9.4.2.2 Partnership & Collaborations
9.4.2.3 Product Launches
9.4.2.4 Expansion
9.4.2.5 Others (Investment, Divestment, Market Penetration, Funding, & Approval)
9.5 List of Key CMOs
For more information about this report visit https://www.researchandmarkets.com/r/tmp4zm
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
